Sanofi vaccine sales face headwinds from US policy shifts

Core Viewpoint - Sanofi anticipates a slight decline in vaccine sales for the year due to changes in U.S. policy, while aiming for high-single-digit overall sales growth by 2026 [1][2] Vaccine Sales - Vaccine sales are expected to be "slightly negative" this year, influenced by U.S. policy changes under President Trump and the impact of anti-vaccine sentiments [1] - CEO Paul Hudson acknowledged a dip in vaccine coverage rates due to public debates and emphasized the need to defend the positive impact of vaccines [2][3] Financial Performance - Sanofi's shares fell nearly 12% in 2025, underperforming the broader European sector index, and remained flat following the results announcement [4] - CFO François-Xavier Roger stated that the company cannot offset the loss of sales from Dupixent once it comes off patent, describing it as "too big to be mitigated" [4] Growth Strategy - Sanofi is focused on cushioning the impact on earnings per share through existing products, new launches expected through 2031, and strategic external acquisitions [5] - The company’s largest deal in 2025 was a $9.5 billion acquisition of Blueprint Medicines, which added Ayvakit to its portfolio [6]